Acute Porphyria Drug Database

D06BX02 - Ingenol Mebutate
Not porphyrinogenic
NP

Rationale
Ingenol mebutate is applied topically and systemic exposure is insignificant.
Chemical description
Diterpene ester
Therapeutic characteristics
Ingenol mebutate is used in the topical treatment of actinic keratosis. The gel is applied once daily to the affected skin area for two or three consecutive days.
Hepatic exposure
Ingenol mebutate 0.5 % gel was applied to a 100 cm2 application area, once daily for two consecutive days, the systemic exposure was less than 0.1 ng/mL and regarded as not quantifiable (Anderson 2014).
Metabolism and pharmacokinetics
Ingenol mebutate is applied topically and is not absorbed systemically (SPC). It is not suspected to be an inducer or an inhibitor of CYP450 enzymes in vitro (Keating 2012). No interaction studies have been performed (SPC).

References

  1. Scientific articles
  2. Anderson L, Jarratt M, et al. Tolerability and Pharmacokinetics of Ingenol Mebutate 0.05% Gel Applied to Treatment Areas up to 100cm(2) on the Forearm(s) of Patients with Actinic Keratosis. J Clin Aesthet Dermatol. 2014 Dec;7(12):19-29. #3155
  3. Keating GM. Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis. Drugs. 2012 Dec 24;72(18):2397-405 #3156
  4. Summary of Product Characteristics
  5. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). (Picato). #3157

Similar drugs
Explore alternative drugs in similar therapeutic classes D06B / D06BX or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙